Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 17/20 | 0.38 |
| ▸ | MMP13 | P45452 | 10/20 | 0.37 |
| ▸ | MMP9 | P14780 | 7/20 | 0.37 |
| ▸ | MMP2 | P08253 | 5/20 | 0.37 |
| ▸ | MMP8 | P22894 | 4/20 | 0.37 |
| ▸ | MMP7 | P09237 | 2/20 | 0.35 |
| ▸ | MMP1 | P03956 | 6/20 | 0.32 |
| ▸ | MMP14 | P50281 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5410704 | 0.81 | CHRM3 (0.37) | ADAM17MMP13MMP9MMP2MMP8 | |
| SCHEMBL14388010 | 0.78 | ACACB (0.33) | — | |
| SCHEMBL83513 | 0.77 | ADAM17 (0.33) | ADAM17MMP13MMP9MMP2MMP8 | |
| SCHEMBL5402113 | 0.73 | CHRM2 (0.36) | CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL395587 | 0.73 | CHRM2 (0.33) | CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL5407812 | 0.73 | POLB (0.36) | CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL5415327 | 0.71 | CHRM2 (0.31) | CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL5394920 | 0.71 | NUDT1 (0.38) | CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL5398630 | 0.71 | GABRP (0.35) | ADAM17CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL5413002 | 0.71 | ALDH1A1 (0.33) | CHRM2CHRM4CHRM5CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7291730-B2 | Pyrimidine compounds and their use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-11-06 | — | — | US | disclosed |
| US-7291730-B2 | Pyrimidine compounds and their use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-11-06 | — | — | US | disclosed |
| US-20050107609-A1 | Pyrimidine compounds and their use | SUMITOMO CHEMICAL COMPANY | 2005-05-19 | — | — | US | disclosed |
| US-6838463-B2 | Pyrimidine compounds and their use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-01-04 | — | — | US | disclosed |
| EP-1366026-B1 | PYRIMIDINE COMPOUNDS AND THEIR USE AS PESTICIDES | SUMITOMO CHEMICAL CO (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-20040077669-A1 | Pyrimidine compounds and their use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-04-22 | — | — | US | disclosed |
| EP-1366026-A2 | PYRIMIDINE COMPOUNDS AND THEIR USE | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002024663-A2 | PYRIMIDINE COMPOUNDS AND THEIR USE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107609-A1 | Pyrimidine compounds and their use | TYMP, TYMS, UMPS | ADAM17 3790/4885MMP13 4556/4885MMP9 4234/4885 |
| US-20040077669-A1 | Pyrimidine compounds and their use | TYMP, TYMS, DPYD | ADAM17 4348/4885MMP13 4715/4885MMP9 4281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.